With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...
Some patients worry about affording their medications as insurers cut coverage for weight-loss drugs
PHILADELPHIA — Mara Nissley has a rare disorder that causes her brain to swell as if she has a tumor. Losing weight can help ...
North Carolina State Treasurer Brad Briner spoke with WRAL News about plans to tackle the state health plan deficit, bringing ...
Plenty of folks have been using GLP-1s — generic versions of popular weight loss drugs such as Ozempic and Zepbound — to jump ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.
Weight loss drugs have surged in popularity. But Gov. Ned Lamont wants CT’s Medicaid program to discontinue covering them for ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Experts aren’t really on board with taking these new, buzzy, multi-ingredient supplements that claim to help with insulin ...
Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.
Join a real-time written chat with WSJ’s Bradley Olson on Monday, March 24, from 3 p.m. to 4 p.m. ET. WSJ subscribers can ...
A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...
A coalition of over 20 leading health organizations is calling on the U.S. Food & Drug Administration (FDA) to enforce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback